Frontlight ResearchEarly access
CompletedPhase 1
Rifaximin in Patients With Monoclonal Gammopathy
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 50 people enrolled
- Started
- 15 May 2019
- Ended
- 30 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Rifaximin
- Record updated
- 26 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Clinical diagnosis of monoclonal gammopathy of undetermined significance based on International Myeloma Working Group (IMWG) criteria
- Patients will be enrolled into one of 3 cohorts:; Cohort A: IgA gammopathy; Cohort B: IgG gammopathy / or light chain gammopathy; Cohort C: IgM gammopathy / asymptomatic macroglobulinemia
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Patients who have received antibiotics within last 3 weeks
- Patients who are receiving any other investigational agents for gammopathy. Patients with clinical myeloma requiring anti-myeloma therapy are also excluded
- The effects of rifaximin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rifaximin administration
- History of allergic reactions or intolerance attributed to rifaximin or compounds of similar chemical or biologic composition to antibiotic under study
Where in United States
- Emory University Hospital/Winship Cancer InstituteAtlanta, United States
About the trial
What the trial wants to find out
This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.
The group in the trial
- Treatment (rifaximin)Treatment being tested
Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.
Treatment: Rifaximin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy
- Record updated
- 26 May 2026